Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma.

Authors:
Justine V Cohen
Justine V Cohen
Pennsylvania Hospital
Ryan J Sullivan
Ryan J Sullivan
Harvard Medical School
United States

Clin Cancer Res 2019 Apr 16. Epub 2019 Apr 16.

Center for Melanoma, Massachusetts General Hospital Cancer Center

The characterization of the MAPK signaling pathway has led to the development of multiple promising targeted therapy options for a subset of patients with metastatic melanoma. The combination of BRAF and MEK inhibitors represents an FDA-approved standard of care in patients with metastatic and resected BRAF mutated melanoma. There are currently three FDA-approved BRAF/MEK inhibitor combinations for the treatment of patients with BRAF mutated melanoma. While there have been significant advances in the field of targeted therapy, further exploration of new targets within the MAPK pathway will strengthen therapeutic options for patients. Important clinical and translational research focuses on mechanisms of resistance, predictive biomarkers, and challenging patient populations such as those with brain metastases or resected melanoma.

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0836DOI Listing
April 2019
4 Reads

Publication Analysis

Top Keywords

targeted therapy
8
patients metastatic
8
mutated melanoma
8
mapk pathway
8
braf mutated
8
melanoma
5
treatment patients
4
combinations treatment
4
inhibitor combinations
4
braf/mek inhibitor
4
patients braf
4
fda-approved braf/mek
4
field targeted
4
advances field
4
melanoma advances
4
therapy exploration
4
three fda-approved
4
standard care
4
fda-approved standard
4
represents fda-approved
4

Similar Publications